Skip to main content

Table 1 Clinical characteristics of two clusters

From: Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer

Characteristic

No (%)

P value

Cluster.1 (N = 219)

Cluster.2 (N = 179)

 

Age

  < 65

72 (18.1%)

77 (19.3%)

 

  >  = 65

147 (36.9%)

102 (25.6%)

0.048 *

Gender

 Female

63 (15.8%)

39 (9.8%)

 

 Male

156 (39.2%)

140 (35.2%)

0.134

Stage

 Stage I-II

45 (11.3%)

83 (20.9%)

 

 Stage III-IV

174 (43.7%)

96 (24.1%)

 < 0.001 ***

T stage

 T0-T2

47 (11.8%)

72 (18.1%)

 

 T3-T4

172 (43.2%)

107 (26.9%)

 < 0.001 ***

Lymph node metastasis

 No

117 (32.9%)

114 (32%)

 

 Yes

88 (24.7%)

37 (10.4%)

 < 0.001 ***

Distant metastasis

 No

77 (37.6%)

117 (57.1%)

 

 Yes

7 (3.4%)

4 (2%)

0.129

  1. †*P < 0.05
  2. **P < 0.01
  3. ***P < 0.001